Aktieanalys

Biosergen Q2 2023: Stable in costs but delays in clinical timeline - Carlsquare

{newsItem.title}

Carlsquare Publicerad: 16 Aug 2023 14:09

Carlsquare Equity Research has published a research update following the Q2 2023 report.

Länk till analysen i sin helhet: https://carlsquare.com/research-update-biosergen-q2-2023-stable-in-costs-but-delays-in-clinical-timeline/

Nyheter om Biosergen

Läses av andra just nu

Om aktien Biosergen

Senaste nytt